Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a caseâcontrol study in China

Luan, Tao; He, Xiaodong; Qu, Qiang; Cai, Lei; Liu, Wei; Zhou, Li; Zhang, Shangming

doi:10.1111/j.1478-3231.2009.02149.x

Cited by 89 publications

(106 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many well conceived case-report studies and one cohort study have demonstrated the association between HBV infection and ICC, with ranges of OR from 2.7 to 9.7 (Cardinale et al, 2010). Our result revealed by multivariate analysis that HBV was independently associated with ICC, which is consistent with the reported findings in China (Zhou et al, 2010) and our previous study (Tao et al, 2010). A US cohort of individuals found HBV nucleic acids in ICC.…”

Section: Discussionsupporting

confidence: 93%

The Metabolic Syndrome and Risk Factors for Biliary Tract Cancer: A Case-control Study in China

Wu¹,

He²,

Yu³

et al. 2012

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Objectives: Recent data show that the metabolic syndrome may play a role in several cancers, but the etiology for biliary tract cancer is incompletely defined. The present aim was to evaluate risk factors for biliary tract cancer in China. Methods: A case-control study in which cases were biliary tract cancer patients referred to Peking Union Medical College Hospital (PUMCH). Controls were randomly selected from an existing database of healthy individuals at the Health Screening Center of PUMCH. Data on the metabolic syndrome, liver diseases, family history, and history of diabetes and hypertension were collected by retrospective review of the patients' records and health examination reports or by interview. Results: A total of 281 patients (102 intrahepatic cholangiocarcinoma (ICC), 86 extrahepatic cholangiocarcinoma (ECC) and 93 gallbladder carcinoma (GC)) and 835 age-and sex-matched controls were enrolled. HBsAg + /anti-HBc + (P=0.002), history of diabetes (P=0.000), cholelithiasis (P=0.000), TC (P=0.003), and HDL (P=0.000) were significantly related to ICC. Cholelithiasis (P=0.000), Tri (P=0.001), LDL (P=0.000), diabetes (P=0.000), Apo A (P=0.000) and Apo B (P=0.012) were significantly associated with ECC. Diabetes (P=0.017), cholelithiasis (P=0.000) and Apo A (P=0.000) were strongly inversely correlated with GC. Conclusion: Cholelithiasis, HBV infection and metabolic symptoms may be potential risk factors for the development of biliary tract cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

The Metabolic Syndrome and Risk Factors for Biliary Tract Cancer: A Case-control Study in China

Wu¹,

He²,

Yu³

et al. 2012

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…Complete surgical resection is currently the only curative treatment for patients with cholangiocarcinoma. However, due to difficulties in the early diagnosis and its high metastatic potential, most patients with cholangiocarcinoma have regional or distant metastasis at the time of clinical diagnosis (3)(4)(5). Few specific diagnostic or therapeutic tools are available because of the limited information on the molecular pathogenesis of cholangiocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells

et al. 2013

View full text Add to dashboard Cite

Abstract. Enhancer of zeste homolog 2 (EZH2) is involved in malignant transformation and the biological aggressiveness of several human malignancies. Growing evidence indicates that EZH2 may be an appropriate therapeutic target for malignancies, including cholangiocarcinoma. Recently, an S-adenosyl-L-homocysteine hydrolase inhibitor, 3-deazaneplanocin A (DZNep) was shown to deplete and inhibit EZH2. The aim of this study was to determine the effect of DZNep and the combination of gemcitabine and DZNep in cholangiocarcinoma cells. The effects of DZNep and its combination with gemcitabine were assessed in the cholangiocarcinoma cell lines RBE and TFK-1. DZNep depleted the cellular levels of EZH2 and inhibited the associated histone H3 lysine 27 trimethylation. DZNep treatment resulted in the inhibition of proliferation in the cholangiocarcinoma cell lines, and the combination of DZNep and gemcitabine showed synergistic inhibition of cell proliferation. DZNep induced apoptosis and G1 phase cell cycle arrest in cholangiocarcinoma cells, and the combination of DZNep and gemcitabine enhanced the induced apoptosis and G1 arrest when compared with gemcitabine alone. Inhibition of cell proliferation by DZNep was partially associated with upregulation of p16INK4a and p17 KIP1. The present study shows that DZNep inhibits cell proliferation by inducing G1 arrest and apoptosis. These results indicate that an epigenetic therapy that pharmacologically targets EZH2 via DZNep may constitute a novel approach for the treatment of cholangiocarcinoma.

show abstract

“…8 Tao LY et al showed that ICC patients had a significantly higher prevalence of HBsAg (27.9 vs. 5.0%) and anti-HBc (without HBsAg) (50.8 vs. 37.6%) than did controls but HBV markers were not significantly different between the ECC cases and the controls. 9 In another Chinese case control study ICC patients had a higher prevalence of HBsAg seropositivity (48.4% vs 9.6%) but not anti-HCV positiviy. In a population based case control study including 535 ICC and 549 ECC cases HCV infection was associated with ICC, but not ECC.…”

Section: Discussionmentioning

confidence: 94%

Hepatitis B and C Virus Infection and Cholangiocarcinoma: A Case-Control Study in Turkey

Önal¹,

Parlak²,

Kekilli³

et al. 2012

UHOD

View full text Add to dashboard Cite

Hepatitis B and C virus (HBV and HCV) infection have been proposed as risk factors for cholangiocarcinoma, but the results are inconsistent through different reports. This study is to carry out a hospital-based case-control study to investigate the association between HBV and HCV infection and cholangiocarcinoma in Turkey. A total of 127 cases and 48 matched controls were included in the study. There were 89 cases with extrahepatic cholangiocarcinoma, 10 cases with intrahepatic cholangiocarcinoma and 28 cases with gallbladder cancer. The patients and controls were questioned on smoking, alcohol drinking, history of cholecystolithiasis, choledocholithiasis and hepatolithiasis. Blood from all participants were tested for HBsAg, Anti-HBs, Anti-HBc IgG and Anti-HCV. The prevalence of smoking, alcohol drinking, cholecystolithiasis, choledocolithiasis, hepatolithiasis, anti-HCV, HBsAg and antiHBs/anti-HbcIgG did not differ significantly between the patients and controls (p>0.05). In the subgroup analysis there was no significantly more prevalent risk factor except smoking in intrahepatic cholangiocarcinoma (p= 0.019). In conclusion, HBV or HCV infection were not found to be risk factors for development of CC in this study. Keywords: Cholangiocarcinoma, Hepatitis B, Hepatitis C ÖZET Hepatit B ve C Virüs Enfeksiyonu ve Kolanjiokarsinom: Türkiye'de Bir Vaka-Kontrol Çal›flmas›Hepatit B ve C virüsü (HBV ve HCV) enfeksiyonu, kolanjiokarsinom için risk faktörleri olarak öne sürülse de, farkl› raporlarda sonuç-lar tutars›zd›r. Bu çal›flmada Türkiye'de HBV ve HCV enfeksiyonu ve kolanjiokarsinom aras›ndaki iliflkiyi araflt›rmak için hastane tabanl› bir vaka-kontrol çal›flmas› yürütülmüfltür. Toplam 127 vaka ve 48 sa¤l›kl› kontrol çal›flmaya al›nd›. 89 olguda ekstrahepatik kolanjiokarsinom, 10 olguda intrahepatik kolanjiokarsinom ve 28 olguda safra kesesi kanseri vard›. Hasta ve kontrol grubundakiler sigara, alkol kullan›m›, kolesistolitiazis, koledokolitiazis ve hepatolitiazis için sorguland›. Tüm kat›l›mc›lar›n kanlar› HBsAg, Anti-HBs, Anti-HBc IgG ve Anti-HCV için test edildi. Hasta ve kontrol grubu aras›nda sigara, alkol kullan›m›, kolesistolitiazis, koledokolitiazis ve hepatolitiazis, anti-HCV, HBsAg ve anti-HBs/anti-HbcIgG prevelans› aç›s›ndan anlaml› fark yoktu (p> 0.05). Alt grup analizinde intrahepatik kolanjiokarsinomda sigara d›fl›nda (p= 0.019) hiçbiri anlaml› risk faktörü olarak görülmedi. çal›flmam›zda HBV ve HCV enfeksiyonlar›, kolanjiokarsinom geliflimi için risk faktörü olarak saptanmam›flt›r.

show abstract

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a caseâcontrol study in China

Abstract: Cirrhosis and chronic hepatitis B virus infection are risk factors for ICC, while cholecystolithiasis, diabetes and previous cholecystectomy are risk factors for ECC.

Cited by 89 publications

References 31 publications

The Metabolic Syndrome and Risk Factors for Biliary Tract Cancer: A Case-control Study in China

The Metabolic Syndrome and Risk Factors for Biliary Tract Cancer: A Case-control Study in China

Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells

Hepatitis B and C Virus Infection and Cholangiocarcinoma: A Case-Control Study in Turkey

Contact Info

Product

Resources

About

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a caseâcontrol study in China

Abstract: Cirrhosis and chronic hepatitis B virus infection are risk factors for ICC, while cholecystolithiasis, diabetes and previous cholecystectomy are risk factors for ECC.

Cited by 89 publications

References 31 publications

The Metabolic Syndrome and Risk Factors for Biliary Tract Cancer: A Case-control Study in China

The Metabolic Syndrome and Risk Factors for Biliary Tract Cancer: A Case-control Study in China

Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells

Hepatitis B and C Virus Infection and Cholangiocarcinoma: A Case-Control Study in Turkey

Contact Info

Product

Resources

About

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a caseâcontrol study in China

Hepatitis B and C Virus Infection and Cholangiocarcinoma: A Case-Control Study in Turkey